Westlake and Ascend close plants, Chemify opens AI-robotics lab, Formation licenses gusacitinib to Sanofi, and more ...

New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

Excessive regulations, the dilution of IP and financial burdens threaten the future of the European pharma industry, warns Sanofi’s John Conway. Register for free to receive our newsletter, view ...

TORONTO (AP) — U.S. President Donald Trump will arrive Sunday for a Group of Seven summit in a country he has suggested should be annexed and as he wages a ...

Chairman, Sanofi Aventis UK. More on this story... Pharmaceutical. Nuvation Bio nabs $250 million to launch cancer drug. 3 March 2025. ... Sanofi licenses gusacitinib from Formation Bio. 24 June 2025.

Sanofi on Monday revealed an aggressive effort to increase supply of Beyfortus, including a plan to begin shipping the shot early in the third quarter. Last year, Beyfortus booked sales of €1.7 ...

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 3:15 pm ...